Vir Biotechnology, Inc. Variable Lease, Cost
Vir Biotechnology, Inc. (VIR) reported Variable Lease, Cost of $8.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-23
- Vir Biotechnology, Inc. variable lease, cost for the quarter ending 2020-12-31 was $599.00K.
- Vir Biotechnology, Inc. variable lease, cost for the quarter ending 2020-09-30 was $460.00K.
- Vir Biotechnology, Inc. variable lease, cost for the quarter ending 2020-06-30 was $646.00K.
- Vir Biotechnology, Inc. variable lease, cost for the quarter ending 2020-03-31 was $594.00K.
- Vir Biotechnology, Inc. variable lease, cost for fiscal 2025 was $8.01M, a 22.31% decline from fiscal 2024.
- Vir Biotechnology, Inc. variable lease, cost for fiscal 2024 was $10.31M, a 6.28% decline from fiscal 2023.
- Vir Biotechnology, Inc. variable lease, cost for fiscal 2023 was $11.00M, a 8.06% increase from fiscal 2022.
- Vir Biotechnology, Inc. variable lease, cost for fiscal 2022 was $10.18M, a 125.28% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $8.01M 10-K · filed 2026-02-23 | ||||
| 2024-12-31 | $10.31M 10-K · filed 2026-02-23 | ||||
| 2023-12-31 | $11.00M 10-K · filed 2026-02-23 | ||||
| 2022-12-31 | $10.18M 10-K · filed 2025-02-27 | $9.94M 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $4.52M 10-K · filed 2024-02-26 | $4.26M 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.06M derived: sum of 2 quarters · filed 2023-02-28 | $1.71M derived: sum of 3 quarters · filed 2023-02-28 | $2.30M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $460.00K 10-Q · filed 2020-11-10 | $1.11M derived: sum of 2 quarters · filed 2020-11-10 | $1.70M 10-Q · filed 2020-11-10 | ||
| 2020-06-30 | $646.00K 10-Q · filed 2020-08-11 | $1.24M 10-Q · filed 2020-08-11 | |||
| 2020-03-31 | $594.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |